SYMBOL : WUHN
SECTOR : PSYCH.
O/S : 48 M
MARKET CAP : $ 15 M
MARKET OPPORTUNITY : UP TO $350 B
M2Bio Sciences is the MOST UNDERVALUED company in the psychedelic market being one of the only companies in the world to have already carried out an in vitro / in vivo study with psilocybin in animals
M2Bio Sciences through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands.
In addition, its new wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best practice science and medicine, clinical research and emerging technologies
M2Bio Science is currently in Pre-enrolment Patient- screening for Phase 1 Human trial.
VERY SMALL FLOAT
M2Bio Science O/S is ONLY 48 millions with a small float of 10 millions
| Researching and developing indications for psilocybin new therapies
| Researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx and Medspresso brands
| Currently in Pre-enrolment Patient- screening for Phase 1 Human trial.
| Cosmetics and FSMP company with cannabinoid and psilocybin research, formulation and delivery system divisions
| First in market to research psilocybin for treatment of alcoholism and cardiovascular tissue
| Established distribution channels in the US, Canada, Europe and Africa
| Early stage entry into cannabinoid and psilocybin company- Enormous upside
| Research undiscovered properties of cannabinoids for treatment of respiratory infectious diseases